On Saturday, Gilead Sciences, Inc. (NASDAQ:GILD) and Merck & Co. Inc. (NYSE:MRK) revealed new results from a Phase 2 clinical ...

Cisgender gay and bisexual men, transgender women, and transgender men remain at higher risk for HIV acquisition.

Thirty-two-year-old Chen Wei-chi has been living with HIV since he was 18. Instead of letting it consume his life, he sought ...

Indigenous communities in Latin America say they are being excluded from the global HIV/AIDS response, leaving them without ...

Doctors and front-line workers are watching closely as HIV rates increase significantly in Alberta.An annual Alberta Health ...

Those include Sunlenca, which is approved for resistant HIV as a twice-yearly injection after an initial oral regimen, and ...

"Madagascar’s HIV epidemic is being fueled by gaps in prevention and glaring inequalities, which urgently need to be ...

The South African National Aids Council is meant to play a co-ordinating role in the country’s response to HIV, bringing ...

Affordability and mass distribution will be critical to the success of a long-lasting injectable HIV prevention drug that has ...

Marine, not her real name, was considering surgery to deal with intense pain. Three doctors refused to see her before a ...

Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today ...

Gilead Sciences Inc. (GILD) and Merck & Co Inc.(MRK) announced new results from a Phase 2 clinical study evaluating the ...